Focus Partners Advisor Solutions’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$325K Buy
9,587
+523
+6% +$17.4K ﹤0.01% 974
2026
Q1
$273K Buy
9,064
+386
+4% +$12.4K ﹤0.01% 1017
2025
Q4
$271K Buy
+8,678
New +$214K ﹤0.01% 917
2025
Q2
– Sell
-12,697
Closed -$195K – 1168
2025
Q1
$195K Buy
12,697
+123
+1% +$2.2K ﹤0.01% 926
2024
Q4
$277K Buy
+12,574
New +$229K ﹤0.01% 622

Other funds holding TEVA

Focus Partners Advisor Solutions's TEVA Position: Q2 2026 in Review

Focus Partners Advisor Solutions increased its Teva Pharmaceutical Industries Limited (TEVA) stake by 5.8% in Q2 2026, buying an estimated $17.4K and bringing the position to 9,587 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Focus Partners Advisor Solutions first reported a position in TEVA in Q4 2024 and has held it in 5 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Focus Partners Advisor Solutions held 9,587 shares of Teva Pharmaceutical Industries Limited worth $325K as of Q2 2026.
  • Focus Partners Advisor Solutions bought 523 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $17.4K.
  • Teva Pharmaceutical Industries Limited made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #974 holding.
  • Focus Partners Advisor Solutions first reported a position in Teva Pharmaceutical Industries Limited in Q4 2024 and has held it in 5 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.